Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Up 954.2% in December

13 Jan 2026, 02:18 by Kim Johansen · The Markets Daily

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,057,055 shares, an increase of 954.2% from the December 15th total of 100,272 shares. Based on an average daily volume of 10,593,738 shares, the days-to-cover ratio is presently 0.1 days. Approximately 42.9% of the shares of the company are short sold. Approximately 42.9% of the shares of the company are short sold. Based on an average daily volume of 10,593,738 shares, the days-to-cover ratio is presently 0.1 days.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO traded up $0.85 during midday trading on Monday, hitting $8.78. The stock had a trading volume of 280,749 shares, compared to its average volume of 6,121,827. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The stock has a 50 day simple moving average of $5.53 and a 200-day simple moving average of $4.61. The company has a market capitalization of $23.00 million, a PE ratio of -1.55 and a beta of 0.71. Ekso Bionics has a 1 year low of $2.73 and a 1 year high of $12.70.

Ekso Bionics (NASDAQ:EKSO – Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.45. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.The firm had revenue of $4.23 million during the quarter, compared to the consensus estimate of $4.16 million. On average, sell-side analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jerome Wong sold 11,288 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the transaction, the chief financial officer owned 26,009 shares of the company’s stock, valued at $124,843.20. This trade represents a 30.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Scott G. Davis sold 23,315 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $111,912.00. Following the transaction, the chief executive officer owned 78,777 shares of the company’s stock, valued at $378,129.60. This represents a 22.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Ekso Bionics

Several large investors have recently bought and sold shares of EKSO. Citadel Advisors LLC purchased a new position in Ekso Bionics in the 3rd quarter worth approximately $198,000. Shay Capital LLC acquired a new stake in shares of Ekso Bionics in the third quarter valued at approximately $67,000. Virtu Financial LLC purchased a new position in Ekso Bionics during the third quarter worth approximately $57,000. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics during the third quarter worth $333,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on EKSO shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. Wall Street Zen raised Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright lowered Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.50.

Check Out Our Latest Research Report on EKSO

Ekso Bionics Company Profile

(Get Free Report)

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.